Modified herpes virus injected into tumors aims to stop melanoma spread

NCT ID NCT06216938

Recruiting now Disease control Sponsor: Yana Najjar Source: ClinicalTrials.gov ↗

First seen Apr 15, 2026 · Last updated May 18, 2026 · Updated 5 times

Summary

This early-phase study tests a treatment called RP1, a modified herpes virus, injected directly into melanoma tumors. The goal is to see if it can kill cancer cells and reduce the risk of the cancer spreading to nearby lymph nodes. The study involves 25 adults with thick or high-risk melanoma who still have visible tumor or positive margins after biopsy. Researchers will monitor side effects and check lymph node samples for cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

MELANOMA